Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Title:
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
Author:
Salvador, J. Manso, L. Haba, J. de la Jaen, A. Ciruelos, E. Villena, M. C. de Gil, M. Murias, A. Galan, A. Jara, C. Bayo, J. Baena, J. M. Casal, J. Mel, J. R. Blancas, I. Sanchez Rvira, P.